Lipantil 200 M, capsules 200 mg, 30 pcs.

Lipantil 200 M is hypolipidemic.

Pharmacodynamics

Lowering triglycerides and, to a lesser extent, cholesterol levels in the blood. Helps to reduce LDL, to a lesser extent – LDL, increases the content of antiatherogenic HDL. Activates lipoprotein lipase and thus influences triglyceride metabolism; disrupts the synthesis of fatty acids and cholesterol, increases the number of LDL receptors in the liver. Fenofibrate reduces platelet aggregation, decreases elevated plasma levels of fibrinogen, may slightly lower blood glucose levels in diabetic patients, reduces blood levels of uric acid.

Pharmacokinetics

The main metabolite is phenofibroic acid. After oral administration, C_max in plasma is reached after 5 h. When administered in a dose of 200 mg, the average plasma concentration is 15 µg/ml. The level of plasma concentration of the drug is stable. T_1/2 of fenofibroic acid is about 20 h. It is excreted mainly with the urine (fenofibroic acid and its glucuronide) in 6 days. It does not cumulate with a single dose and prolonged use. Fenofibroic acid is not excreted by hemodialysis.

Indications

Hypercholesterolemia (type IIa), endogenous hypertriglyceridemia (types: IIb, III (isolated and mixed), IV) that cannot be corrected by diet in adults.

Active ingredient

Composition

Active substance:

phenofibrate micronized200 mg;

Associates:

sodium lauryl sulfate;

lactose;

Pregelatinized starch;

crosspovidone;

magnesium stearate;

titanium dioxide;

iron oxide;

gelatin

How to take, the dosage

Ingestively, with food. The recommended dosage (if the doctor has not prescribed otherwise) is 1 capsule per day. The course of treatment is determined by the doctor.

Interaction

Combinations that are contraindicated: with other fibrates – increased risk of side effects (muscle damage).

Indesirable combinations: with HMG-CoA reductase inhibitors – increased risk of side effects (muscle damage).

Combinations to be used with caution – with indirect anticoagulants (risk of bleeding). More frequent monitoring of PV during indirect anticoagulant dose selection during treatment with fibrates and for 8 days after their withdrawal is necessary.

Phenofibrate is not used concomitantly with MAO inhibitors.

Contraindications

Severe hepatic and renal dysfunction, history of phototoxic or photoallergic reactions when treated with fenofibrates or other similar drugs, especially ketoprofen, combination with other fibrates, children under 18 years of age, pregnancy, lactation, congenital galactosemia, lactase deficiency.

Side effects

Gastrointestinal disorders: dyspepsia. Increased level of liver transaminase activity in blood serum.

Allergic reactions: rare – skin rashes, itching, urticaria, photosensitization. In some cases (after several months of use) photosensitivity reactions in the form of erythema, papules, vesicles or eczematous rashes may develop.

Similarities